Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

PaxVax sales and marketing update

November 3, 2016 10:43 PM UTC

PaxVax launched Vaxchora (PXVX0200) in the U.S. to prevent cholera caused by serogroup O1 in adults aged 18 to 64 traveling to cholera-affected areas. The live attenuated vaccine against Vibrio choler...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

PaxVax Inc.